Andrea Miyahira hosts Marina Sharifi about a multiomic profiling study of metastatic castration-resistant prostate cancer using circulating tumor cells, ctDNA, and RNA sequencing.

PSMA and Beyond 2025 CAR-T and Bispecific antibodies targeting PSMA, Poseida trial, neuroendocrine prostate cancer, STEAP-1.

PSMA and Beyond 2025 CA-IX in renal cell cancer (RCC), ZIRCON, kidney cancer, stage migration for RCC, REDECT trial, renal mass biopsy, girentuximab.

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

SNMMI 2025 utility of the PROSTest to predict response to 177Lu-PSMA therapy in metastatic castration resistant prostate cancer (mCRPC), blood-based 27-marker gene mRNA expression machine ...